«It’s a sign the sector is maturing — even though investment in European healthtechs is down 42% this year compared with the frothy days of 2021, according to Dealroom. But that drop is mostly at later stages, and €2bn has been raised in seed and pre-seed funding alone in 2022. That’s just €300m less than the figure raised by early-stage healthtech startups last year (excluding €100m-plus megarounds that aren’t really seed stage) and with a month left on the clock and a reporting lag to account for, that number will only go up.»

«The fund will invest in startups across Europe, mainly at pre-seed and seed, that it thinks can hit profitability in the next couple of years. YZR is on the hunt for medical technology startups, disruptors on the delivery side of healthcare and pure digital direct-to-consumer or B2B health solutions.»

«YZR doesn’t do biotech deals — because investing in that sector requires more of a scientific background, says Markus Feuerecker, YZR’s other cofounder and a former private equity investor. Another no-go (for the moment, at least) are startups built to go to market on Germany’s DiGA — a regulatory framework meaning digital health companies can be prescribed free to the patient and reimbursed by the state.»

Article written by KAI NICOL-SCHWARZ